Allogene Therapeutics
South San Francisco
CA
United States
194 articles about Allogene Therapeutics
-
South San Francisco-based Allogene Therapeutics released some early data from its Phase I UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.
-
Allogene Therapeutics Reports Third Quarter 2020 Financial Results
11/4/2020
Enrollment Ongoing in Phase 1 Trials of ALLO-501 (ALPHA), ALLO-501A (ALPHA2) and ALLO-715 (UNIVERSAL) Initial Phase 1 Results from the UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma to be Presented at a Medical Meeting in Q4 2020 In 1H 2021, Initial ALLO-501A Data and Updated ALLO-501 Results in Non-Hodgkin Lymphoma are Planned in Preparation for a Potential Pivotal Study Initiation of ALLO-501A in 2021 Three Investigational New Drug (IND) Applications to be Submitted; Two in Q4 2020
-
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology
11/4/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will present initial data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T therapy, in relapsed/refractory multiple myeloma in an oral presentation at the 62nd Annual Meeting of the American Society of Hematology (ASH)
-
Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020
10/27/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report third quarter 2020 financial results on Wednesday, November 4, 2020, prior to the open of the market.
-
Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)
10/15/2020
Clinical and Translational Research Collaboration Will Evaluate Multiple AlloCAR T Candidates Across the Allogene Portfolio Targeting Multiple Tumor Types
-
Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation
10/1/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the Jefferies Virtual Cell Therapy Summit in October 2020. Jefferies Virtual Cell Therapy Summit Tuesday, October 6, 2020 12:30 PM PT/3:30 PM ET This webcast will be made available on the Company's website at w
-
Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation
9/2/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following virtual investor conferences in September 2020.
-
Allogene Therapeutics Reports Second Quarter 2020 Financial Results
8/5/2020
Initial Phase 1 Results from the ALLO-501 ALPHA Trial at ASCO Demonstrated an Overall Response Rate of 75% and Complete Response Rate of 44% in CAR T Naïve Relapsed/Refractory Non-Hodgkin Lymphoma Patients
-
Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020
7/28/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and con
-
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
7/7/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D. to its Scientific Advisory Board (SAB). The SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development. “We are privileged to we
-
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
7/1/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that Ton Schumacher, Ph.D., Principal Investigator at the Netherlands Cancer Institute and chair of Allogene’s Scientific Advisory Board, has been award
-
Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Research (AACR) Virtual 2020 Meeting
6/22/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that preclinical findings supporting DLL3-targeted AlloCAR T therapy in small cell lung cancer (SCLC) and inducible TurboCAR™
-
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
6/22/2020
FLT3-Directed AlloCAR T™ Therapy Demonstrated Potent Anti-Leukemic Activity in Pre-Clinical Models Without Evidence of Off-Target Activity
-
Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
6/3/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following June 2020 virtual investor conferences. Jefferies Virtual Healthcare Conference June 3, 2020 10:30 AM PT/1:30 PM ET Goldman Sachs 41st Annual Global Healthcare Conference June 9, 2020 7:30 AM PT/10
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
6/2/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share.
-
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock - Jun 01, 2020
6/1/2020
Allogene Therapeutics, Inc., announced the commencement of an underwritten public offering of $450.0 million of shares of its common stock.
-
The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.
-
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting
5/29/2020
ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) In the Ongoing Study, 22 Patients were Evaluable for Safety and 19 Patients Were Evaluable for Efficacy with at Least One Tumor Assessment as of Data Cutoff Seven Complete Responses (CR) and Five Partial Responses (PR) were Observed for an Overall Response Rate (ORR) of 63% and CR Rate of 37% Higher Response Rates
-
Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020
5/26/2020
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results from the ALLO-501 ALPHA Phase 1 trial in relapsed/refractory non-Hodgkin lymphoma on May 29, 2020 via a live webinar at 5:30 AM Pacific Time/8:30 AM Eastern Time.
-
American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
5/13/2020
ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host Disease